Kyocera funding phase 2 Progenza OA trials and as Leo Lee indicated manufactured product for treatment aimed for 2023. With phase 2 trials anticipated to be successful it is reasonable to expect Kyocera would want other major jurisdiction rights if not worldwide.
AGC a major shareholder converted shares at .16 and is assisting RGS to achieve its objectives. With RGS now well funded the company is clearly in a position to advance its R&D strategy.
RGS is partnered with highly resourceful companies which mitigates risks to an extent.
RGS Price at posting:
15.5¢ Sentiment: Hold Disclosure: Held
